These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25663885)

  • 1. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.
    Deng Q; Li JY; Liu PJ; Zhao MF
    Oncol Lett; 2015 Mar; 9(3):1217-1220. PubMed ID: 25663885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
    Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
    Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
    BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
    Hong M; Zhu H; Sun Q; Zhu Y; Miao Y; Yang H; Qiu HR; Li JY; Qian SX
    Aging (Albany NY); 2020 Apr; 12(7):5792-5811. PubMed ID: 32238611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Efficacy of Decitabine Combined with Modified CAG Regimen for Relapse/Refractory Acute Myeloid Leukemia with AML1-ETO
    Liu Q; Fei XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1334-1338. PubMed ID: 27784352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
    Zhang JL; Cao YP; Li JG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
    Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
    Jing Y; Zhu CY; Zhang Q; Niu JH; Yang H; Liu SY; Zhu HY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1245-50. PubMed ID: 25338566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
    Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
    Kong FC; Qi L; Zhou YL; Yu M; Huang WF; Li F
    Curr Med Sci; 2023 Dec; 43(6):1151-1161. PubMed ID: 38057538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
    Zhu CY; Liu SY; Niu JH; Zhang Q; Yang H; Zhu HY; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):88-93. PubMed ID: 25687052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
    Wu M; Ma IX; Xie YH; Ye XJ; He HS; Hua JS; Yang RY; Wang XH; Wang XQ; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1991-1997. PubMed ID: 33283731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
    Lei M; Liu L; Wang Z; Wu D
    Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
    Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.